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Cylindrical hydrogels of hydroxyethyl methacrylate (HEMA) and ethylene glycol dimetha- 
crylate (EGDMA) as crosslinking agent were prepared by radical polymerization at 7O’C. 
After washing they were soaked in an aqueous drug solution of antipyrine or theophylline. 
The in vitro drug release experiments were performed in 100 ml i~tonic glucose at 37°C. 
Rectal administration of a hydroge~prepa~tion conta~n~~gantipyr~ne was performed in two 
subjects for 72 h. With a theuphy~line-conta~ni~ hydrogel preparation rectal drug adminis- 
tration was performed in six volunteers for 24 h. Plasma and saliva samples were taken 
regularly and the in vivo drug release was determined by means of a deconvoiution proce- 
dure. In vitro 1.12gantipyrine had been released according to a matrix-type profile for 72 h, 
whereas it was calculated that this was 1.13 and 1.09 g in vivo in the two subjects. The re- 
lease profile in vivo was very similar to that in vitro. The theophylline hydrogelpreparation 
released in vitro a total of 288 ZL 6 mg of drug in 24 h and in vivo this amount was calculated 
to be 288 + 11 mg (mean rt s.d.). Near-constant plasma theophylline concentrations were 
obtained after administering the hydrogel preparation. In all six subjects the cumulative 
drug profile was in almost perfect a~eement with that observed in vitro. Hydrogeis offer 
interesting perspectives as rate-~on~o~led rectal drug delivery systems because of the pre- 
dictable release profile in vivo on the basis of obse~at~ns in a simple in vitro model. 
INTRODUCTION 
Hydrogels, defined as hydrophilic polymers 
which are able to contain a considerable 
amount of water without dissolving, form an 
important class of polymeric materials which 
can be used as drug delivery systems. Since 
*To whom correspondence should be addressed; 
present address: Pharm. R&D, Organon Int., P.O. Box 
20, 5340 BH Oss, The Netherlands. 
the introduction of a synthetic hydrogel, 
poly(hydroxyethy1 methacrylate) (poly-HE- 
MA) in 1960 [ 1 ] , extensive research has been 
performed in the area of biomedical use of 
hydrogels [2, 31. Such investigations aim at 
the preparation of well-controlled rather than 
sustained-release delivery systems containing 
bioactive agents. For a ate-controlled drug 
delivery system a consistent correlation be- 
tween the release characteristics in vivo and 
those in vitro is considered to be the most im- 
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portant feature. Investigations with controlled- 
release hydrogel preparations with a relatively 
short period of drug release are scarce. Very 
few studies have been published in which non- 
disintegrating hydrogel matrices were design- 
ed to be administered by the oral or rectal 
route [ 4-71. A hydrogel-procainamide prep- 
aration has been given orally to rabbits, which 
resulted in a prolonged release profile com- 
pared to a conventional capsule. Morphine- 
loaded poly( ethyleneglycol)-base hydrogels 
administered rectally to four patients exhibited 
near constant and prolonged drug delivery, 
but in uiuo release was found to be slower 
than in vitro. The rectal route is very suitable 
for drug administration [B], and in previous 
studies a rate-controlled osmotic drug delivery 
system was successfully applied in healthy 
subjects [ 9-121. 
In contrast to data in viva the in vitro 
release characteristics of drugs and solutes 
from hydrogels of HEMA and ethylene glycol 
dimethacrylate (EGDMA) as crosslinking 
agent have been described extensively [13- 
151. In the present study in uiuo investiga- 
tions with hydrogels of the HEMA and 
EGDMA type containing antipyrine or theo- 
phylline as active substance are described. 
Their plasma and saliva level profiles were 
studied after rectal administration in healthy 
volunteers. Hydrogel drug preparations can be 
made by mixing the drug with the monomer 
mixture followed by polymerization, or by 
impregnating the hydrogel with drug solu- 
tions. With the latter soaking technique pos- 
sible residual monomers or initiator can be 
removed from the system before drug loading 
[6, 13,161 and therefore this method is to be 
preferred for the preparation of drug delivery 
systems. 
Hydrogels were made with antipyrine as a 
model compound since it is highly water- 
soluble and well absorbed rectally, while plas- 
ma sampling can be replaced by saliva sam- 
pling [ 91. Theophylline was used (as the 
water-soluble choline salt) since it is frequent- 
ly applied rectally in actual practice and has 
a relatively low therapeutic index [B, lo]. 
With conventional oral and rectal dosage 
forms and even with some of the sustained- 
release or retard formulations an optimal 
and in uiuo predictable plasma concentra- 
tion-time profile is not achieved. A relatively 
constant rate of drug input would be most 
desirable in theophylline prophylactic therapy. 
MATERIALS AND METHODS 
Materials 
Ultrapure HEMA (Hydromed. Sci., New 
Brunswick, NJ, U.S.A.), EGDMA (Fluka AC, 
Buchs, Switzerland) and 2,2’-azobisisobutyro- 
nitrile (AIBN) (Polysciences, Warrington, PA, 
U.S.A.) were used. HEMA contained 0.04% 
methacrylic acid, 0.15% EGDMA and 0.02% 
diethylene glycol methacrylate, and was used 
as received. EGDMA was purified, by extrac- 
tion with 1 M NaOH several times, washing 
with water and drying afterwards. Antipyrin 
and choline theophyllinate, pharmacopoeia1 
quality (Brocacef, Maarssen, The Netherlands) 
were used as received. 
Preparation of hydrogels 
Hydrogel preparation no. I consisted of a 
monomer mixture of HEMA/EGDMA 100/l 
(w/w) with 20 weight percent of water and 
preparation no. II of a HEMA/EGDMA 40/l 
mixture with 40 weight percent of water. 
Both solutions were polymerized after degas- 
sing, in the presence of 7.84 mmol AIBN per 
liter monomer mixture in a cylindrical glass 
mold of 11 mm i.d. at 70°C for 15 h. After 
polymerization the hydrogels were rinsed 
with water at 37°C for 4 weeks and dried 
afterwards at 100°C for 4 days. Hydrogel 
preparation no. I was soaked in an aqueous 
solution of antipyrine (150 mg/ml) and no. II 
in an aqueous choline theophyllinate solution 
(180 mg/ml) at room temperature until 
equilibrium was reached. This was determined 
by in vitro release experiments. Equilibrium 
was assumed to have been reached when no 
further increase in the total amount of re- 
leased drug was observed. Before the drug 
release experiments cylinders of the desired 
length (34 mm) were cut. 
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In vitro release experiments 
The in vitro release experiments were per- 
formed in a glass flask equipped with a mag- 
netic stirrer in 100 ml isotonic solution (5.5% 
glucose) at 37.0 f 02°C. Since the model 
drugs are highly water-soluble, sink conditions 
were always maintained. At regular time inter- 
vals samples were taken and replaced by the 
same volume of glucose solution; drug con- 
centrations were determined spectrophoto- 
metrically (Perkin Elmer DB 124). 
Subjects and drug administration 
Eight healthy male volunteers, age 22-34, 
weight 60-78 kg, participated after medical 
examination. All had given informed consent. 
Two of them participated in the antipyrine 
study and six in the study with theophylline. 
The latter study was approved by the Com- 
mittee for Medical Ethics of the University 
Hospital and the faculty of Medicine, Univer- 
sity of Leiden. 
In the antipyrine study one hydrogel drug 
preparation was kept in the rectum for 72 h. 
Drug administration started at 9 a.m.; saliva 
samples were collected at regular time inter- 
vals during 96 h. When the subjects had to 
empty their bowels during the 72 h of drug 
administration, the hydrogel was recovered, 
cleaned and inserted again. 
Rectal drug administration of the theo- 
phylline-containing hydrogel preparation took 
place during 24 h. Drug administration started 
at 9 a.m. and after 12 h the system was re- 
moved and replaced by a second one, which 
was kept in the rectum for another 12 h. 
Blood samples were taken just before rectal 
application and after 0.25, 0.5, 0.75, 1, 1.5, 
2,3,4,6,8,10, 12,15, 19,22,24,28, 31, 34 
and 37 h from a cannula in a forearm vein. 
Plasma samples were obtained by centrifuging 
the heparinized blood samples immediately 
after blood sampling. Saliva samples were 
collected at regular time intervals in the 
period from 14 to 40 h when blood sampling 
was less frequent. Plasma and saliva samples 
were stored at -20°C until assayed. The hy- 
drogels were administered, if possible, after 
defecation. When the subjects had a bowel 
movement during the 24 h of drug administra- 
tion the same procedure was followed as de- 
scribed above. The intake of caffeine was pro- 
hibited from 24 h before drug administration 
onwards until the last sample had been col- 
lected. 
Assay of antipyrine and theophylline in saliva and 
plasma 
The antipyrine and theophylline concentra- 
tions were determined according to previously 
described methods [9, lo], except that with 
the assay of theophylline, antipyrine was used 
as an internal standard and the chromato- 
graphic conditions were modified: a radial- 
pak C 8 reverse phase column with an eluent 
of 0.03 M acetate buffer (pH 4.0) with 4% 
tetrahydrofuran. Linear calibration curves 
were obtained from 0.2 to 10 pg theophyl- 
line/ml saliva or plasma. 
Calculations and pharmacokinetic analysis 
The total dose administered rectally was 
calculated from the difference between the 
amount in the hydrogel before application 
and the amount remaining after application. 
The latter amount was determined by in vitro 
release afterwards until no further increase in 
the drug concentration could be found. 
The total area under the plasma or saliva 
concentration-time curves (AUC) was calcu- 
lated according to a method described by 
Chiou [ 171. The clearance values were deter- 
mined by dividing the total dose administered 
by AUC. The elmination rate constant (k,l) 
was obtained by regression analysis of the 
logarithm of plasma or saliva concentration 
against time after withdrawal of the hydrogel. 
Elimination half-lives (tl,+l) were calculated 
as ts,l = 0.693/k,l. 
Each time a sample was taken the cumula- 
tive amount released in vivo was determined 
by means of a deconvolution procedure 
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(point area method) which calculated the 
actual input by relating the input to a unit 
impulse response function [18]. For each in- 
dividual this function was calculated from the 
k,, and the clearance as determined at the end 
of the rectal experiment. 
RESULTS 
The in vitro release of antipyrine and theo- 
phylline from hydrogel preparations I and II 
were measured under stirred and non-stirred 
conditions. There were no significant differ- 
ences between continuous stirring and stirring 
for 10 s once every hour just before sample 
taking. The very reproducible drug release 
from preparation I in isotonic glucose was in 
agreement with a matrix-type profile and 
after 72 h 82 t 2% (1.12 g; n = 3) of the total 
amount of antipyrine was present in the dis- 
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Fig. 1. Mean cumulative in vitro release of theophyl- 
line from a hydrogel preparation versus time (with 
s.d.) and versus the square root of time (n = 5). 
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Fig. 2. Saliva concentration time profile of antipyrine 
after rectal administration of an antipyrine hydrogel 
preparation during 72 h in subjects I(o) and II (0). 
solution medium. The in vitro drug release 
from preparation II containing theophylline 
is shown in Fig. 1. In 12 h the hydrogel re- 
leased 144 + 3 mg (calculated as theophyl- 
line) which was 80% of the total amount in 
the dosage form, 
Figure 2 shows the saliva concentration- 
time curves of antipyrine after rectal adminis- 
tration of the hydrogel preparation to the two 
I.2 , 
Fig. 3. Cumulative amount of antipyrine released 
from a hydrogel preparation in vitro (solid line) and 
in uiuo after rectal application during 72 h in subject I 
(0) and II (0). 
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Fig. 4. Plasma (*) and saliva (0) theophylline concen- 
tration time profiles after rectal administration of a 
hydrogel preparation to subjects B and C. Time of 
insertion (t ), renewal ($ ) and withdrawal (4 ). 
subjects. The administered dose was 1.13 and 
1.09 g antipyrine for subjects I and II, respec- 
tively; the AUC, clearance and k,l were 0.52 
and 0.44 g h/l, 2.2 and 2.5 l/h, and 0.065 and 
0.047 h-l respectively. Figure 3 shows the 
cumulative amount of antipyrine released in 
uiuo, as calculated with the deconvolution 
method, together with the release profile in 
vitro (solid line). A very good agreement of 
the antipyrine release in uiuo with that in 
vitro is obtained. With this drug delivery sys- 
tem the amount and rate of release of anti- 
pyrine after rectal application in man seems 
to be quite predictable on the basis of in vitro 
experiments. 
The theophylline concentration-time 
curves in plasma and saliva after rectal ad- 
ministration of the hydrogels to subject B and 
5. 0 
I 
I I 
Fig. 5. Mean plasma concentration time profile after 
rectal administration of a theophylline hydrogel 
preparation (with s.d.; n = 6). Time of insertion (t ), 
renewal ($ ) and withdrawal (J ). 
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C are given in Fig. 4. A rapid increase in plas- 
ma concentration was found for the first 4 to 
5 h and from then onwards the concentration 
remained almost constant until the hydrogel 
preparation was replaced by a second one. 
Again the plasma concentrations rose relative- 
ly rapidly for 4 to 5 h and then remained 
nearly constant until the dosage form was re- 
moved. During the period of almost constant 
theophylline concentrations and during the 
elimination phase the saliva plasma concen- 
tration ratio was reasonably constant. The 
plasma concentration-time curves were quite 
similar in all six subjects; in Fig. 5 the mean 
curve with standard deviations is shown. In 
Table 1 the administered dose, AUC, k,l and 
ts,l are given together with the calculated 
clearance values. The mean elimination half- 
life was 5.1 h and the mean clearance value 
3.7 l/h. The mean dose administered rectally 
with the hydrogel preparations during 24 h 
was 288 + 11 mg, which corresponds perfect- 
ly with the in vitro results. Figure 6 shows 
the cumulative in uiuo release of theophyl- 
line, calculated according to the deconvolu- 
tion method, in all six subjects together with 
the mean in vitro release profile (solid line). 
In all cases the profile in uiuo showed an al- 
most perfect agreement with the situation 
found in vitro in isotonic glucose. 
The hydrogels with theophylline or anti- 
pyrine were well tolerated by all subjects and 
no complaints of inconvenience or irritation 
were reported. 
TABLE 1 
Calculated doses and pharmacokinetic data following rectal administration of a theophylline-containing hydrogel 
preparation to six healthy volunteers 
dose O-12 h dose 12-24 h total dose h,, AUC clearance 
(mg) (mg) (mg) (h-‘) (erg h/ml) :s; (l/h) 
A 142 152 294 0.144 94.3 4.8 3.1 
B 140 132 272 0.107 77.2 6.5 3.5 
C 136 150 286 0.121 75.7 5.7 3.8 
D 149 152 301 0.173 89.3 4.0 3.4 
E 145 150 295 0.133 67.5 5.2 4.4 
F 133 146 279 0.150 70.8 4.6 3.9 
mean t s.d. 141 * 6 147 ?r 8 288 z? 11 0.138 + 0.021 79.1 * 10.5 5.1 c 0.8 3.7 + 0.4 
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Fig. 6. Cumulative amount of theophylline released from two hydrogels subsequently, each during 12 h, in vitro 
(solid line) and in uivo (m) after rectal application, in all individuals. 
DISCUSSION 
The results of the present study clearly in- 
dicate that it is quite possible to obtain a 
reproducible and predictable in uiuo drug 
release profile with a hydrogel drug delivery 
system. Since the release characteristics can 
be varied quite easily by for instance the 
geometry, the diameter, the crosslinking agent, 
the amount of crosslinker and the water con- 
tent [6, 14, 19, 201, hydrogels offer interest- 
ing perspectives for rate-controlled rectal 
delivery of several drugs. 
With the hydrogel preparation containing 
theophylline, with a relatively high drug load 
and crosslinker percentage, an almost constant 
release was obtained for some time, leading to 
quite constant plasma concentration levels. 
However, the drug release profile from the 
hydrogels is of a matrix type, which means 
that the release rate decreases continuously. 
In principle there are possibilities to get a 
zero-order rate of release from hydrogels 
when drugs with short elimination half-lives 
other than our model drugs, are used. Lee et 
al. [ 211 introduced rate-controlling barriers 
by soaking the hydrogel outer layer with 
crosslinker followed by -iradiation. A zero- 
order release of progesterone in vitro was 
demonstrated. Also a change in geometry to 
23 
cylinder-type sections or to hemispheric 
matrices coated with an impermeable layer 
except for an exposed cavity in the centre 
face, can be used to achieve nearly zero-order 
release kinetics in vitro [ 19, 221. Using swel- 
ling systems a flattening of the release rate 
versus time profile can be obtained [7]. 
In the present investigation the hydrogels 
were loaded with drugs by means of a soaking 
technique, which is rather time-consuming. 
This procedure was chosen in order to be able 
to wash the hydrogels after polymerization to 
ensure that no monomers or initiator were 
present in the final preparations [6, 13, 161. 
When the drug is dissolved in the monomer 
mixture before polymerization, the hydrogels 
cannot be washed without loss of drug. 
Whether the impregnation or soaking tech- 
nique could be further improved or accelerat- 
ed remains the subject of further studies. 
The antipyrine and theophylline elimina- 
tion half-lives and clearance values obtained 
after application of the rectal drug delivery 
systems were comparable to previously ob- 
tained data [9, lo] and to data described in 
the literature [23-251. The deconvolution 
method used to describe the in uiuo drug re- 
lease profile requires an impulse response 
function which was derived from the experi- 
mental clearance values and elimination rate 
constants. In this procedure it is assumed that 
clearance and elimination rate constant are 
constant throughout the experiment, absorp- 
tion is complete and that the dose entering 
the systemic circulation equals the total 
cumulative amount released in rho. These 
assumptions are not unreasonable, because 
both antipyrine and theophylline (as choline 
salt), when administered in solution and at a 
relatively slow rate, are well absorbed rectally 
[9, lo]. An i.v. experiment performed at the 
same time as the rectal one, for instance by 
using theophylline and labelled theophylline, 
would theoretically lead to a better impulse 
response function. However, since large intra- 
individual differences in clearance may exist, 
with changes of up to 40% within a few weeks 
[lo, 251, an i.v. experiment before or after 
the rectal experiment may not be very mean- 
ingful. 
CONCLUSION 
The release characteristics of both anti- 
pyrine and theophylline from a hydrogel 
preparation of HEMA crosslinked with 
EGDMA in duo, when applied rectally in 
healthy volunteers, were almost identical to 
those observed in vitro. It is evident that 
hydrogel systems, applicable to a large num- 
ber of different drugs, have great potential as 
flexible rectal drug delivery systems. Large 
scale production and in uiuo studies with dif- 
ferent drugs should reveal the possibilities of 
replacing conventional rectal dosage forms by 
synthetic hydrogel drug preparations. 
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